Literature DB >> 18794262

Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque.

Seigo Ishino1, Takahiro Mukai, Yuji Kuge, Noriaki Kume, Mikako Ogawa, Nozomi Takai, Junko Kamihashi, Masashi Shiomi, Manabu Minami, Toru Kita, Hideo Saji.   

Abstract

UNLABELLED: Lectinlike oxidized low-density lipoprotein (LDL) receptor 1 (LOX-1), a cell surface receptor for oxidized LDL, has been implicated in vascular cell dysfunction related to plaque instability, which could be a potential target for an atherosclerosis imaging tracer. In this study, we designed and prepared (99m)Tc-labeled anti-LOX-1 monoclonal IgG and investigated its usefulness as an atherosclerosis imaging agent.
METHODS: Anti-LOX-1 monoclonal IgG and control mouse IgG2a were labeled with (99m)Tc after derivatization with 6-hydrazinonicotinic acid to yield (99m)Tc-LOX-1-mAb and (99m)Tc-IgG2a, respectively. Myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits (atherosclerosis model) and control rabbits were injected intravenously with these probes, and in vivo planar imaging was performed. At 24 h after the injection, the aortas were removed, and radioactivity was measured. Autoradiography and histologic studies were performed with serial aortic sections.
RESULTS: The level of (99m)Tc-LOX-1-mAb accumulation was 2.0-fold higher than the level of (99m)Tc-IgG2a accumulation in WHHLMI rabbit aortas, and the level of (99m)Tc-LOX-1-mAb accumulation in WHHLMI rabbit aortas was 10.0-fold higher than the level of (99m)Tc-LOX-1-mAb accumulation in control rabbit aortas. In vivo imaging clearly visualized the atherosclerotic aortas of WHHLMI rabbits. Autoradiography and histologic studies revealed that regional (99m)Tc-IgG2a accumulation was independent of the histologic grade of the lesions; however, regional (99m)Tc-LOX-1-mAb accumulation was significantly correlated with LOX-1 expression density and the vulnerability index. The highest level of (99m)Tc-LOX-1-mAb accumulation, expressed as {radioactivity in region of interest (Bq/mm(2))/[injected radioactivity (Bq)/animal body weight (g)]} x 10(2), was found in atheromatous lesions (3.8 +/- 1.1 [mean +/- SD]), followed in decreasing order by fibroatheromatous lesions (2.0 +/- 1.0), collagen-rich lesions (1.6 +/- 0.8), and neointimal lesions (1.4 +/- 0.7).
CONCLUSION: The level of (99m)Tc-LOX-1-mAb accumulation in grade IV atheroma was higher than that in neointimal lesions or other, more stable lesions. Nuclear imaging of LOX-1 expression with (99m)Tc-LOX-1-mAb may be a useful means for predicting atheroma at high risk for rupture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794262     DOI: 10.2967/jnumed.107.049536

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  The association between soluble lectin-like oxidized low-density lipoprotein receptor-1 levels and patients with isolated coronary artery ectasia.

Authors:  Mehmet Balin; Ahmet Celik; M Ali Kobat
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

2.  Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.

Authors:  Dayuan Li; Amit R Patel; Alexander L Klibanov; Christopher M Kramer; Mirta Ruiz; Bum-Yong Kang; Jawahar L Mehta; George A Beller; David K Glover; Craig H Meyer
Journal:  Circ Cardiovasc Imaging       Date:  2010-05-04       Impact factor: 7.792

Review 3.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.

Authors:  Thibaut Quillard; Peter Libby
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

4.  Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.

Authors:  Jens De Vos; Iris Mathijs; Catarina Xavier; Sam Massa; Ulrich Wernery; Luc Bouwens; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

Review 5.  Imaging Macrophage-associated Inflammation.

Authors:  Catherine A Foss; Julian Sanchez-Bautista; Sanjay K Jain
Journal:  Semin Nucl Med       Date:  2018-02-13       Impact factor: 4.446

6.  Capping it off.

Authors:  H William Strauss
Journal:  J Nucl Cardiol       Date:  2009-07-25       Impact factor: 5.952

7.  Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.

Authors:  Yuji Kuge; Nozomi Takai; Yuki Ogawa; Takashi Temma; Yan Zhao; Kantaro Nishigori; Seigo Ishino; Junko Kamihashi; Yasushi Kiyono; Masashi Shiomi; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

Review 8.  Molecular imaging in cardiovascular disease: Which methods, which diseases?

Authors:  Jonathan R Lindner; Albert Sinusas
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

9.  Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET.

Authors:  Yongjian Liu; Dana Abendschein; Geoffrey E Woodard; Raffaella Rossin; Kyle McCommis; Jie Zheng; Michael J Welch; Pamela K Woodard
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 10.  Molecular imaging in atherosclerosis.

Authors:  Andor W J M Glaudemans; Riemer H J A Slart; Alessandro Bozzao; Elena Bonanno; Marcello Arca; Rudi A J O Dierckx; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.